# NCT06107686 (NCT06107686)

> A Study of YL202 in Selected Patients With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06107686
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Conditions: NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors
- Interventions: YL202 should be intravenously infused
- Enrollment: 200
- Primary outcome: ORR assessed according to RECIST v1.1
- Primary outcome: Determination of the recommended dose of YL202 in the pivotal clinical study

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 4
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06107686